Daisuke Ando

Dr. Daisuke Ando

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 January 2024 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
DADaisuke Ando
Daisuke Ando
MMMegumi Miyatsuji
Megumi Miyatsuji
HSHideyuki Sakoda
Hideyuki Sakoda
EYEiichi Yamamoto
Eiichi Yamamoto
TMTamaki Miyazaki
Tamaki Miyazaki
KIKen-ichi Izutsu
Ken-ichi Izutsu
Dissolving microneedles (MNs) are novel transdermal drug delivery systems that can be painlessly self-administered. This study investigated the effects of experimental conditions on the mechanical characterization of dissolving MNs for quality evaluation. Micromolding was used to fabricate polyvinyl alcohol (PVA)-based dissolving MN patches with eight different cone-shaped geometries. Axial force mechanical characterization test conditions, in terms of compression speed and the number of compression needles per test, significantly affected the needle fracture force of dissolving MNs. Characterization using selected test conditions clearly showed differences in the needle fracture force of dissolving MNs prepared under various conditions. PVA-based MNs were divided into two groups that showed buckling and unbuckling deformation, which occurred at aspect ratios (needle height/base diameter) of 2.8 and 1.8, respectively. The needle fracture force of PVA-based MNs was negatively correlated with an increase in the needle’s aspect ratio. Higher residual water or higher loading of lidocaine hydrochloride significantly decreased the needle fracture force. Therefore, setting appropriate methods and parameters for characterizing the mechanical properties of dissolving MNs should contribute to the development and supply of appropriate products.

23 March 2023 in Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
KIKen-ichi Izutsu
Ken-ichi Izutsu
DADaisuke Ando
Daisuke Ando
TMTokio Morita
Tokio Morita
YAYasuhiro Abe
Yasuhiro Abe
HYHiroyuki Yoshida
Hiroyuki Yoshida

1 May 2012 in Neurochemistry International
Verified
Journal Article
Closed access
DADaisuke Ando
Daisuke Ando
YKYoshiyuki Kubo
Yoshiyuki Kubo
SAShin-ichi Akanuma
Shin-ichi Akanuma
DYDaisuke Yoneyama
Daisuke Yoneyama
MTMasanori Tachikawa
Masanori Tachikawa
KHKen-ichi Hosoya
Ken-ichi Hosoya

3 November 2023 in Pharmaceutical Research
Verified
Journal Article
Closed access
PDF file
DADaisuke Ando
Daisuke Ando
AOAisa Ozawa
Aisa Ozawa
MSMotoharu Sakaue
Motoharu Sakaue
EYEiichi Yamamoto
Eiichi Yamamoto
TMTamaki Miyazaki
Tamaki Miyazaki
KIKen-Ichi Izutsu
Ken-Ichi Izutsu

15 April 2021 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
MIMasaki Inoue
Masaki Inoue
KYKanako Yamashita
Kanako Yamashita
YTYuta Tsuji
Yuta Tsuji
MMMidori Miki
Midori Miki
SAShota Amano
Shota Amano
STShin-Ichi Tsunoda
Shin-Ichi Tsunoda
Regulatory T cells (Tregs) are a subpopulation of lymphocytes that play a role in suppressing and regulating immune responses. Recently, it was suggested that controlling the functions and activities of Tregs might be applicable to the treatment of human diseases such as autoimmune diseases, organ transplant rejection, and graft-versus-host disease. TNF receptor type 2 (TNFR2) is a target molecule that modulates Treg functions. In this study, we investigated the role of TNFR2 signaling in the differentiation and activation of mouse Tregs. We previously reported the generation of a TNFR2-selective agonist TNF mutant, termed R2agoTNF, by using our unique cytokine modification method based on phage display. R2agoTNF activates cell signaling via mouse TNFR2. In this study, we evaluated the efficacy of R2agoTNF for the proliferation and activation of Tregs in mice. R2agoTNF expanded and activated mouse CD4+CD25+ Tregs ex vivo. The structural optimization of R2agoTNF by internal cross-linking or IgG-Fc fusion selectively and effectively enhanced Treg expansion in vivo. Furthermore, the IgG-Fc fusion protein suppressed skin-contact hypersensitivity reactions in mice. TNFR2 agonists are expected to be new Treg expanders. Key Points A TNFR2 agonist, R2agoTNF, selectively and preferentially expands Tregs in mice. Structural optimization of R2agoTNF increased Tregs via enhanced TNFR2 signaling. scR2agoTNF-Fc is a potential drug to suppress contact hypersensitivity.

24 August 2021 in Drug Delivery and Translational Research
Verified
Journal Article
Closed access
PDF file
DADaisuke Ando
Daisuke Ando
TMTamaki Miyazaki
Tamaki Miyazaki
EYEiichi Yamamoto
Eiichi Yamamoto
TKTatsuo Koide
Tatsuo Koide
KIKen-Ichi Izutsu
Ken-Ichi Izutsu